Biotech

All Articles

BMS trenches TIGIT, bowing out $200M bank on Agenus bispecific

.Bristol Myers Squibb is actually axing one more large bet coming from the Caforio period, canceling...

Nuvation halts wager inhibitor after looking at period 1 record

.After looking at stage 1 record, Nuvation Biography has decided to stop deal with its single top BD...

' Medical intuitiveness' led FDA experts to support Zevra's rare condition med

.Zevra Therapies' uncommon condition medicine seems to be to become on the course to permission this...

Pfizer takes $230M reached after axing neglected DMD genetics treatment

.Pfizer's period 3 Duchenne muscle dystrophy (DMD) gene treatment breakdown has actually gone a $230...

AC Immune finds 'spots' potential in Alzheimer's medicine data

.After greater than twenty years of work with neurodegenerative diseases, Swiss biotech a/c Invulner...

GSK goes down ph. 2 HPV injection over lack of best-in-class possible

.GSK has actually ditched a stage 2 human papillomavirus (HPV) vaccination from its pipe after choos...

OS Therapies refiles $6M IPO to cash HER2 medicine, preclinical ADCs

.Operating system Therapies will definitely specify on the NYSE American supply swap today through a...

ALX's waning CD47 action rate delivers supply spiraling down

.ALX Oncology's stage 2 stomach cancer cells reaction price has damaged. After observing its CD47 bl...

Ionis axes eye condition coming from intendeds of Roche-partnered prospect after information let down

.Yet Another of Ionis Pharmaceuticals' key midphase readouts has actually disappointed expectations,...

Biogen's chief executive officer mentioned no risky handle 2023. He's ready to be daring

.While Biogen's pharma peers are hunting for late-stage resources along with little bit of danger, c...